Detailed answers about CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING, including incorporation, status, business activity, and accounts information.
When was CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING founded?
CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING was officially incorporated on 21 June 1993 and is registered under company number GE000052. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING?
United Kingdom Economic Interest Grouping. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations.
What is the current status of CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING?
CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING do?
CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING operates in the following sector: 5146 - Wholesale of pharmaceutical goods. This provides insight into the company's primary business activity and industry focus.
What is CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING's registered address?
The registered office address of CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING is CAPITAL HOUSE, 22 CRAVEN ROAD, LONDON, UNITED KINGDOM, W2 3PX. This is the official address filed with Companies House for legal and statutory correspondence.
Is CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING financially stable?
Financial accounts for CADUCEUS PHARMACEUTICALS UK ECONOMIC INTEREST GROUPING are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.